Brain Development—Shedding Light on Opioid Exposure and Health Disparities

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Developmental Neuroscience".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 191

Special Issue Editor


E-Mail Website
Guest Editor
Department of Psychiatry, University of Alberta Faculty of Medicine and Dentistry, Edmonton, AB T6G 2R7, Canada
Interests: .psychopathology; clinical psychiatry; psychopharmacology; addiction psychology

Special Issue Information

Dear Colleagues,

Opioids can negatively impact brain development in fetuses and adolescents, affecting brain size, structure, and function. These effects can lead to cognitive and behavioral deficits later in life.

Opioids can affect the brain in the following ways:

  • Brain size: Opioids can reduce the size of the brain's basal ganglia, thalamus, and cerebellar white matter.
  • Myelination: Opioids can impair the development of myelin, the fatty insulation that helps electrical signals travel through nerve fibers.
  • Connectivity: Opioids can alter the connectivity between parts of the brain.
  • White matter: Opioids can cause white matter lesions or signal abnormalities.
  • Neuroanatomical volumes: Opioids can reduce cortical surface areas and lead to thin cortices.

Opioids can cause long-lasting changes in brain development, increasing the risk of addiction and cognitive dysfunction, as well as vulnerability to delirium, hallucinations, and cognitive impairment in older adults.

For this Special Issue, we welcome papers showcasing advanced research on the impact of opioids on brain development. We encourage the submission of original papers, review articles, case reports and case series, pilot studies, and randomized controlled clinical trials.

Dr. Adam Abba-Aji
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • opioids
  • brain development
  • cognition
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 675 KiB  
Article
Cannabis Use in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Reasons for Use
by Markus Backmund, Greta G. Zámbó, Susanne Schöfl and Michael Soyka
Brain Sci. 2025, 15(7), 699; https://doi.org/10.3390/brainsci15070699 - 29 Jun 2025
Viewed by 70
Abstract
Background and aims: Opioid maintenance therapy (OMT) is the first-line treatment for opioid use disorder (OUD), reducing opioid use and mortality while improving physical and mental health. However, concomitant substance use remains common, with cannabis being the most frequently used substance. This study [...] Read more.
Background and aims: Opioid maintenance therapy (OMT) is the first-line treatment for opioid use disorder (OUD), reducing opioid use and mortality while improving physical and mental health. However, concomitant substance use remains common, with cannabis being the most frequently used substance. This study assessed the prevalence and clinical correlates of cannabis use in OMT patients, as well as individual motivations. Methods: In this cross-sectional, single-center study, 128 OUD patients (96 male, 32 female) receiving OMT were assessed using standardized questionnaires: the Marijuana Smoking History Questionnaire (MSHQ), Cannabis Problems Questionnaire (CPQ) and the Severity of Dependence Scale (SDS). Cannabis users and non-users were compared regarding type (methadone vs. buprenorphine) and dosage of maintenance medication. Results: Cannabis use was reported by 41% of patients, 73% met criteria for cannabis dependence, 30% of the full sample. Of the patients, 85% reported cannabis-related legal issues. Common reasons for use included recreational motives (mood change, enhancement) and reduction in cravings for other substances. Cannabis dependence was significantly more common in patients receiving buprenorphine than methadone. Higher methadone doses were also associated with increased cannabis use. These results suggest a clinically relevant pattern. Conclusions: Cannabis use is highly prevalent and appears to be influenced by type and dosage of substitution medication. These findings highlight a complex interaction between opioid treatment and cannabis use, possibly involving behavioral coping or regulatory processes. Further longitudinal and placebo-controlled trials are needed to investigate the clinical and pharmacological interactions between cannabis and OMT, including effects on craving, withdrawal, and overall treatment outcomes. Full article
Show Figures

Graphical abstract

Back to TopTop